Integra LifeSciences (IART 6.31%), a medical technology company specializing in neurosurgery, reconstructive, and tissue technologies, released its results for Q2 2025 on July 31, 2025. The most important takeaway was that the company's revenue (GAAP) exceeded expectations, coming in at $415.6 million—well above the GAAP consensus estimate of$395.0 million. Adjusted EPS (non-GAAP) slightly surpassed forecasts as well, hitting $0.45 compared to the expected$0.44. Despite this sales outperformance, Integra ...